TY - JOUR
T1 - Molecular allergology and its impact in specific allergy diagnosis and therapy
AU - Barber, Domingo
AU - Diaz-Perales, Araceli
AU - Escribese, Maria M.
AU - Kleine-Tebbe, Jörg
AU - Matricardi, Paolo M.
AU - Ollert, Markus
AU - Santos, Alexandra F.
AU - Sastre, Joaquin
N1 - Funding Information:
This work was supported by Instituto de Salud Carlos III (Project numbers PI19/00044 and PI18/01467). This work was also supported by the grant from Ministerio de Ciencia, Innovación y Universidades RTI2018‐095166‐B‐I00.
Funding Information:
We thank Tomas Barker‐Tejeda for the critical reading of the manuscript. Dr. Barber reports personal fees from ALK, AIMMUNE, grants from ALK, Allero therapeutics, outside the submitted work. Dr. Kleine‐Tebbe reports personal fees from Allergen Online (Nebraska, USA), personal fees from Allergy Therapeutics, personal fees from Allergopharma, personal fees from ALK‐Abelló, personal fees from AstraZeneca, personal fees from Bencard, personal fees from Dr. Pfleger, grants and personal fees from GSK, personal fees from HAL Allergy, personal fees from InfectoPharm, personal fees from LETI, grants and personal fees from Lofarma, grants and personal fees from Novartis, personal fees from Merck US, personal fees from Sanofi Genentech, grants and personal fees from Stallergenes‐Greer, personal fees from Springer International Publishers, personal fees from ThermoFisher Scientific, personal fees from Thieme Publishers, Germany, non‐financial support from American Academy Allergy Asthma and Immunology, non‐financial support from European Academy of Allergy and Clinical Immunology, personal fees and non‐financial support from German Society of Allergy and Clinical Immunology, non‐financial support from WHO/IUIS Allergen nomenclature subcommittee, outside the submitted work. Dr. Matricardi reports personal fees from TPS, grants, personal fees and non‐financial support from Thermo Fisher Scientific, grants and personal fees from Hycor, personal fees from Omron, grants from Stallergens, grants and personal fees from Euroimmun, outside the submitted work; Dr. Matricardi reports personal fees from TPS, grants, personal fees and non‐financial support from Thermo Fisher Scientific, grants and personal fees from Hycor, grants and personal fees from Omron, grants from Stallergens, grants and personal fees from Euroimmun, outside the submitted work. Dr. Ollert reports personal fees from HycorDiagnostics, outside the submitted work. Dr. Sastr reports grants and personal fees from SANOFI, personal fees from GSK, personal fees from NOVARTIS, personal fees from ASTRA ZENECA, personal fees from MUNDIPHARMA, personal fees from FAES FARMA, outside the submitted work. All other authors have nothing to disclose.
Publisher Copyright:
© 2021 The Authors. Allergy published by European Academy of Allergy and Clinical Immunology and John Wiley & Sons Ltd.
PY - 2021/12
Y1 - 2021/12
N2 - Progressive knowledge of allergenic structures resulted in a broad availability of allergenic molecules for diagnosis. Component-resolved diagnosis allowed a better understanding of patient sensitization patterns, facilitating allergen immunotherapy decisions. In parallel to the discovery of allergenic molecules, there was a progressive development of a regulation framework that affected both in vitro diagnostics and Allergen Immunotherapy products. With a progressive understanding of underlying mechanisms associated to Allergen immunotherapy and an increasing experience of application of molecular diagnosis in daily life, we focus in analyzing the evidences of the value provided by molecular allergology in daily clinical practice, with a focus on Allergen Immunotherapy decisions.
AB - Progressive knowledge of allergenic structures resulted in a broad availability of allergenic molecules for diagnosis. Component-resolved diagnosis allowed a better understanding of patient sensitization patterns, facilitating allergen immunotherapy decisions. In parallel to the discovery of allergenic molecules, there was a progressive development of a regulation framework that affected both in vitro diagnostics and Allergen Immunotherapy products. With a progressive understanding of underlying mechanisms associated to Allergen immunotherapy and an increasing experience of application of molecular diagnosis in daily life, we focus in analyzing the evidences of the value provided by molecular allergology in daily clinical practice, with a focus on Allergen Immunotherapy decisions.
KW - allergen immunotherapy
KW - component-resolved diagnosis
KW - food allergy
KW - major allergen
KW - respiratory allergy
UR - http://www.scopus.com/inward/record.url?scp=85108360515&partnerID=8YFLogxK
UR - https://pubmed.ncbi.nlm.nih.gov/34057744
U2 - 10.1111/all.14969
DO - 10.1111/all.14969
M3 - Review article
C2 - 34057744
AN - SCOPUS:85108360515
SN - 0105-4538
VL - 76
SP - 3642
EP - 3658
JO - Allergy: European Journal of Allergy and Clinical Immunology
JF - Allergy: European Journal of Allergy and Clinical Immunology
IS - 12
ER -